Drug Trial Radar · NCT03793166
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,175
Planned (sponsor's estimate)
Start
Jun 7, 2019
Primary completion
Mar 1, 2028
Study completion Mar 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known how well the combination of cabozantinib and nivolumab after initial treatment with ipilimumab and nivolumab works in treating patients with renal cell cancer that has spread to other parts of the body.
Conditions
- Clear Cell Renal Cell Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Lymph Nodes
- Metastatic Malignant Neoplasm in the Soft Tissue
- Metastatic Malignant Neoplasm in the Viscera
- Rhabdoid Tumor of the Kidney
- Sarcomatoid Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
Bone ScanProcedure
Undergo bone scan
CabozantinibDrug
Given PO
Computed TomographyProcedure
Undergo CT scan
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From registration to date of death from any cause for non-randomized patients, from time of randomization until death from any cause for randomized patients, assessed up to 5 years
Locations
859 sites in 2 countries. Site status is shown where the registry gives one.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Highlands Oncology Group - Rogers
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Community Cancer Institute
Clovis, California
University Oncology Associates
Clovis, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Kaiser Permanente-Ontario
Ontario, California
Kaiser Permanente - Panorama City
Panorama City, California
Kaiser Permanente-Riverside
Riverside, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-Rio San Diego
San Diego, California
Kaiser Permanente-San Diego Zion
San Diego, California
Sharp Memorial Hospital
San Diego, California
Naval Medical Center -San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Showing 40 of 859 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.